Inozyme Pharma, Inc. (INZY)
NASDAQ: INZY · Real-Time Price · USD
1.360
-0.020 (-1.45%)
At close: Feb 4, 2025, 4:00 PM
1.390
+0.030 (2.21%)
After-hours: Feb 4, 2025, 7:17 PM EST
Inozyme Pharma Stock Forecast
INZY's stock price has decreased by -74.39% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Inozyme Pharma stock have an average target of 17.75, with a low estimate of 11 and a high estimate of 30. The average target predicts an increase of 1,205.15% from the current stock price of 1.36.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Inozyme Pharma stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 5 | 5 | 5 |
| Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 7 | 7 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $43 → $30 | Buy | Maintains | $43 → $30 | +2,105.88% | Jan 13, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $14 → $11 | Buy | Maintains | $14 → $11 | +708.82% | Jan 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $14 → $16 | Strong Buy | Maintains | $14 → $16 | +1,076.47% | Jan 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $14 → $16 | Strong Buy | Maintains | $14 → $16 | +1,076.47% | Jan 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +929.41% | Nov 6, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.63
from -1.37
EPS Next Year
-1.57
from -1.63
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | 39.1M | |||
| Avg | n/a | n/a | 10.5M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.59 | -1.06 | -0.96 | |||
| Avg | -1.63 | -1.57 | -1.68 | |||
| Low | -1.64 | -1.96 | -2.19 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.